Phase 4 Study on Olmesartan, an Angiotensin Receptor Blocker, on Ambulatory Blood Pressure Change, Vitamin D Levels and Urinary Sodium Excretion of Patients With Hypertension.
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 09 Dec 2009 Planned number of patients changed from 200 to 100 as reported by ClinicalTrials.gov.
- 06 Mar 2009 New trial record